Bionime (TPE:4737) Short-Term Debt: NT$1,190 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4737 Bionime Corp TPE:4737
63 GF Score
Price NT$56.00
GF Value NT$58.61
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bionime Short-Term Debt?

Bionime TPE:4737 -0.36% 63 Short-Term Debt is NT$1,190 Mil as of Dec. 2025. GuruFocus rates TPE:4737 with a GF Score™ of 63/100 and a GF Value™ of NT$58.61 (Fairly Valued). The stock has 7 warning signs investors should review.

Bionime's Short-Term Debt for the quarter that ended in Dec. 2025 was NT$1,190 Mil.

Bionime's quarterly Short-Term Debt declined from Jun. 2025 (NT$1,200 Mil) to Sep. 2025 (NT$1,112 Mil) but then increased from Sep. 2025 (NT$1,112 Mil) to Dec. 2025 (NT$1,190 Mil).

Bionime's annual Short-Term Debt increased from Dec. 2023 (NT$1,110 Mil) to Dec. 2024 (NT$1,577 Mil) but then declined from Dec. 2024 (NT$1,577 Mil) to Dec. 2025 (NT$1,190 Mil).

Bionime Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Bionime Short-Term Debt Related Terms

Bionime Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Bionime's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionime Short-Term Debt Chart

Bionime Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 869.72 775.68 1,109.96 1,577.28 1,190.06

Bionime Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,577.28 1,280.48 1,200.24 1,111.85 1,190.06
TPE:4737
63GF Score
Bionime Corp TPE:4737
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of NT$1,190 Mil mean?
Bionime (TPE:4737) has a Short-Term Debt of NT$1,190 Mil as of Dec. 2025.
Is Bionime's Short-Term Debt too high?
Bionime's current Short-Term Debt is NT$1,190 Mil. Overall, Bionime has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's Short-Term Debt compare to ISRG and BDX?
Bionime's Short-Term Debt of NT$1,190 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Bionime's current Short-Term Debt is NT$1,190 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.61, compared to a current price of NT$56.00 — trading 4.5% below its estimated fair value. The current Short-Term Debt is NT$1,190 Mil. Bionime's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Bionime (TPE:4737), the current Short-Term Debt is NT$1,190 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionime (TPE:4737) Overvalued in 2026?

Based on GuruFocus' analysis, Bionime stock appears to be undervalued. The current stock price of NT$56.00 is trading 4.5% below its estimated GF Value™ of NT$58.61. GuruFocus considers Bionime to be Fairly Valued.

Key valuation signals for TPE:4737:

  • Short-Term Debt: NT$1,190 Mil
  • GF Value™: NT$58.61 vs. price of NT$56.00 (4.5% below fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bionime Business Description

Address No. 100, Daqing Street, Section 2, South District, Taichung, TWN, 40242
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
63GF Score

Get the complete analysis for TPE:4737

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$56.00
Price
NT$58.61
GF Value